CHENGDU, Chine, 25 décembre 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX : 02162) a annoncé aujourd'hui que l'Administration nationale des produits médicaux (la « NMPA ») de Chine a récemment approuvé la demande supplémentaire d'autorisation de nouveau médicament (« NDA ») de...
Hence then, the article about keymed biosciences annonce l approbation de stapokibart pour le traitement de la rhinosinusite chronique avec polypose nasale was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences annonce l'approbation de Stapokibart pour le traitement de la rhinosinusite chronique avec polypose nasale )
Also on site :
- Hot French startup ZML releases free product to speed inference across lots of AI chips
- Lionel Messi ‘match-fixing’ conspiracy is all Fifa’s own fault
- ‘Elize: Shadows Of A Woman’ Trailer: Netflix Brazil Feature Based On Case Explored In ‘Elize Matsunaga: Once Upon a Crime’